Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Determination of genes downstream of the BRAF oncogene and PTEN tumour suppressor gene responsible for melanoma malignancy and metastasis in melanoma cell culture and mouse knockout models
FY 2011-12
Summary
Due to Canada's growing and aging population, the number of new cancer cases has increased tremendously. Cancer is also a growing global burden, with millions of new cases diagnosed and cancer-related deaths reported each year worldwide. As a result, research to find effective treatments for cancer has become a pressing matter. Researchers have realized that understanding the biochemical and genetic basis of cancer is fundamental in developing rational therapeutic strategies to effectively treat cancer. Skin cancers (e.g. melanoma) are known for their resistance to therapeutic treatment, aggressiveness, and tendency to spread (i.e. metastasize) resulting in lethal effects. Mutation of the oncogene BRAF and tumour suppressor gene PTEN, leading to their activation and silencing, respectively, are prevalent in human melanoma. BRAF protein inhibitors have been developed to treat melanoma, but often patients become resistant to this treatment after the initial response. This research proposal describes a project using BRAF activated, PTEN silenced cell culture and mouse melanoma models to determine the gene products that work downstream of BRAF and PTEN which are responsible for the malignant conversion and acquisition of metastatic characteristics of melanoma cells. Using gene silencing technologies, genes that work downstream of BRAF and PTEN will be silenced in a sequential fashion in melanoma cell culture models. Successful candidates, i.e. the silenced genes that prevent cancerous growth, will be verified in mouse models to determine whether the gene silencing prevents melanoma formation/progression in a whole organism. Identifying these downstream contributors to melanoma formation is key in developing new targeted and effective therapeutic options for this dreaded disease.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
253802
Name
de Bruyns Angeline
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Determination of genes downstream of the BRAF oncogene and PTEN tumour suppressor gene responsible for melanoma malignancy and metastasis in melanoma cell culture and mouse knockout models
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Research; Gene Knockdown; In Vitro Cell Culture Models; Melanoma Cancers; Mouse Disease Models
Abstract
Due to Canada's growing and aging population, the number of new cancer cases has increased tremendously. Cancer is also a growing global burden, with millions of new cases diagnosed and cancer-related deaths reported each year worldwide. As a result, research to find effective treatments for cancer has become a pressing matter. Researchers have realized that understanding the biochemical and genetic basis of cancer is fundamental in developing rational therapeutic strategies to effectively treat cancer. Skin cancers (e.g. melanoma) are known for their resistance to therapeutic treatment, aggressiveness, and tendency to spread (i.e. metastasize) resulting in lethal effects. Mutation of the oncogene BRAF and tumour suppressor gene PTEN, leading to their activation and silencing, respectively, are prevalent in human melanoma. BRAF protein inhibitors have been developed to treat melanoma, but often patients become resistant to this treatment after the initial response. This research proposal describes a project using BRAF activated, PTEN silenced cell culture and mouse melanoma models to determine the gene products that work downstream of BRAF and PTEN which are responsible for the malignant conversion and acquisition of metastatic characteristics of melanoma cells. Using gene silencing technologies, genes that work downstream of BRAF and PTEN will be silenced in a sequential fashion in melanoma cell culture models. Successful candidates, i.e. the silenced genes that prevent cancerous growth, will be verified in mouse models to determine whether the gene silencing prevents melanoma formation/progression in a whole organism. Identifying these downstream contributors to melanoma formation is key in developing new targeted and effective therapeutic options for this dreaded disease.
Competitiondate
201202
Approvedterm2
1 yr 0 mth
Pinamesdelim
de Bruyns, Angeline
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~